Page last updated: 2024-10-15

5,10-methylenetetrahydrofolic acid

Description

5,10-methylenetetrahydrofolic acid: RN refers to parent cpd(L-Glu)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135400185
CHEMBL ID117348
CHEBI ID20502
SCHEMBL ID4097748
SCHEMBL ID16413214
MeSH IDM0060648

Synonyms (43)

Synonym
5,10-methylenetetrahydrofolic acid
CHEBI:20502 ,
n-{4-[3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9h)-yl]benzoyl}-l-glutamic acid
5,10-methylene-tetrahydrofolate
n-(4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo(1,5-f)pteridin-8(9h)-yl)benzoyl)-l-glutamic acid
5,10-methylene-5,6,7,8-tetrahydrofolate
ch2h4folate
tetrahydromethylenefolate
n5,n10-methylene-5,6,7,8-tetrahydrofolic acid
CHEMBL117348
5,10-methylenetetrafolate
folitixorin
(2s)-2-[[4-(3-amino-1-oxo-4,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl)benzoyl]amino]pentanedioic acid
l-glutamic acid, n-(4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo(1,5-f)pteridin-8(9h)-yl)benzoyl)-
folitixorin [inn]
unii-0sxy5et48b
0sxy5et48b ,
n5,n10-methylenetetrahydropteroylglutamic acid
5,10-methylenetetrahydrofolic acid [dsc]
folitixorin [who-dd]
folic acid, tetrahydro-n5,n10-methylene-
n5,n10-methylenetetrahydrofolic acid
5,10-methylene-(6rs)-tetrahydrofolic acid
5,10-methylene-5,6,7,8-tetrahydrofolic acid
SCHEMBL4097748
l-glutamic acid,n-[4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-f]pteridin-8(9h)-yl)benzoyl]-
SCHEMBL16413214
mfcd19443704
5,10-methylenetetrahydrofolate (mthf/folitixorin)
methylenetetrahydrofolate
QYNUQALWYRSVHF-ABLWVSNPSA-N
n5,n10-methylene-tetrahydrofolic acid
l-glutamic acid,n-(4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-f]pteridin-8(9h)-yl)benzoyl)-
Q192838
methylenetetrahydrofolic acid
(2s)-2-(4-(3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9h)-yl)benzamido)pentanedioic acid
MS-28345
DTXSID90955873
HY-14769
folitixorin (~80%)
(2s)-2-[[4-(3-amino-1-oxo-2,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl)benzoyl]amino]pentanedioic acid
CS-0003550
AKOS040744808

Pharmacokinetics

ExcerptReference
" Plasma was collected for pharmacokinetic (PK) analysis before, during, and after surgery."( A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study.
Derwinger, K; Kodeda, K; Odin, E; Taflin, H; Wettergren, Y, 2015
)

Compound-Compound Interactions

ExcerptReference
" The objective of this phase 1 dose de-escalation trial was to estimate the minimum tolerated dose of [6R]-MTHF to be used in combination with pemetrexed 500 mg/m(2) in the neoadjuvant treatment of patients with rectal cancer."( Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.
Björkqvist, H; Carlsson, G; Derwinger, K; Gibson, F; Gustavsson, B; Kurlberg, G; Odin, E; Swartling, T, 2015
)
"Adult patients (≥18 years) with resectable rectal adenocarcinoma were allocated to [6R]-MTHF doses of 500, 100, 50, and 10 mg/m(2) in combination with pemetrexed 500 mg/m(2)."( Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.
Björkqvist, H; Carlsson, G; Derwinger, K; Gibson, F; Gustavsson, B; Kurlberg, G; Odin, E; Swartling, T, 2015
)
"The results of this phase 1 study indicate that the estimated minimum tolerated dose of [6R]-MTHF was 100 mg/m(2) once weekly in combination with pemetrexed 500 mg/m(2)."( Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.
Björkqvist, H; Carlsson, G; Derwinger, K; Gibson, F; Gustavsson, B; Kurlberg, G; Odin, E; Swartling, T, 2015
)
" The haematological toxicity score in combination with the dUr levels at C1-24 h and C4-24 h predicted early clinical response (p = 0."( Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.
Carlsson, G; Gustavsson, B; Odin, E; Taflin, H; Tell, R; Wettergren, Y, 2021
)

Bioavailability

ExcerptReference
"The natural folate derivative, 5-methyltetrahydrofolate ([6S]-5-MTHF), could be an option for supplementation and fortification but its bioavailability remains unclear."( The short-term bioavailabilities of [6S]-5-methyltetrahydrofolate and folic acid are equivalent in men.
Connolly, E; Krämer, K; McKillop, DJ; McNulty, H; McPartlin, JM; Molloy, A; Pentieva, K; Reichert, R; Scott, JM; Strain, JJ; Ward, M, 2004
)

Dosage Studied

ExcerptReference
" Groups of tumor bearing mice were treated with saline, leucovorin, 5-fluorouracil or 5-fluourouracil plus leucovorin on an optimal dosage schedule."( Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo.
Dreyfuss, A; el-Magharbel, I; Frei, E; Holden, SA; Jones, SM; Rosowsky, A; Trites, D; Wright, JE, 1989
)
" The rate of this chemical reaction for the three drugs correlated with the amount of the tetrahydroquinolines formed by incubation with the soluble fraction and in orally dosed rats."( The formaldehyde-donating activity of N5,N10-methylene tetrahydrofolic acid in xenobiotic biotransformation.
Kucharczyk, N; Sofia, RD; Wong, KK; Yang, JT, 1984
)
" Continuous subcutaneous infusion at the same total dosage over 3 days gave AUC (0-96 hr) values of 134 nmol/mg protein."( Leucovorin and folic acid regimens for selective expansion of murine 5,10-methylenetetrahydrofolate pools.
Alperin, W; Pardo, M; Rosowsky, A; Sayeed-Shah, U; Wright, JE, 1995
)
" A common dosage of leucovorin in adjuvant and palliative settings is 60 mg/m(2)."( Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages.
Derwinger, K; Odin, E; Taflin, H; Wettergren, Y, 2014
)
" Further studies are needed to establish whether higher dosage yields a better treatment response."( Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages.
Derwinger, K; Odin, E; Taflin, H; Wettergren, Y, 2014
)
"Thirty-two patients scheduled for colon resection were randomized to receive Modufolin® or Isovorin® at dosage of 60 or 200 mg/m²."( A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study.
Derwinger, K; Kodeda, K; Odin, E; Taflin, H; Wettergren, Y, 2015
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
methylenetetrahydrofolic acid
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency5.86820.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency5.86820.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Canalicular multispecific organic anion transporter 1Rattus norvegicus (Norway rat)Ki269.00000.84004.968210.0000AID679311
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidylate synthaseLacticaseibacillus caseiKm14.50001.44004.33505.7000AID1147654; AID212845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1147650Growth inhibition of Pediococcus cerevisiae ATCC 8081 up to 5 ug/mL1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid.
AID679311TP_TRANSPORTER: inhibition of DNP-SG uptake in bile canalicular membrane vesicles from SD rat1998The American journal of physiology, 10, Volume: 275, Issue:4
Reduced folate derivatives are endogenous substrates for cMOAT in rats.
AID1147627Activity of Lactobacillus casei thymidylate synthetase at 3 x 10'-4 M by spectrophotometric analysis1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid.
AID1147651Growth inhibition of Streptococcus faecium ATCC 8043 up to 5 ug/mL1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid.
AID1147647Induction of growth of Pediococcus cerevisiae ATCC 8081 up to 5 ug/mL1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid.
AID1147630Activity of Lactobacillus casei thymidylate synthetase assessed as release of [3H] from [5-3H]-deoxyuridine 5' phosphate at 3 x 10'-4 M1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid.
AID1147652Growth inhibition of Lactobacillus casei ATCC 7469 up to 5 ug/mL1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid.
AID1147654Activity of Lactobacillus casei thymidylate synthetase by spectrophotometric analysis1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid.
AID1147637Inhibition of Lactobacillus casei thymidylate synthetase using dl-5,10-Methylene tetrahydropteroyl-L-glutamate as substrate at 6.3 x 10'-5 M relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid.
AID1147624Inhibition of Lactobacillus casei thymidylate synthetase using l-5,10-Methylene tetrahydropteroyl-L-glutamate as substrate at 6.3 x 10'-5 M by spectrophotometric analysis1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid.
AID1147649Induction of growth of Lactobacillus casei ATCC 7469 up to 5 ug/mL1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid.
AID1147648Induction of growth of Streptococcus faecium ATCC 8043 up to 5 ug/mL1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid.
AID212845Michaelis-Menten constant (Km) against thymidylate synthase2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Fragment-based drug discovery.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (208)

TimeframeStudies, This Drug (%)All Drugs %
pre-199046 (22.12)18.7374
1990's75 (36.06)18.2507
2000's51 (24.52)29.6817
2010's32 (15.38)24.3611
2020's4 (1.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (4.67%)5.53%
Reviews11 (5.14%)6.00%
Case Studies3 (1.40%)4.05%
Observational0 (0.00%)0.25%
Other190 (88.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]